Powell D R, Liu F, Baker B K, Hintz R L, Durham S K, Brewer E D, Frane J W, Tonshoff B, Mehls O, Wingen A M, Watkins S L, Hogg R J, Lee P D
Baylor College of Medicine, Houston, Texas 77030, USA.
J Clin Endocrinol Metab. 1997 Sep;82(9):2978-84. doi: 10.1210/jcem.82.9.4215.
Previous studies suggest that growth retardation in children with chronic renal failure (CRF) results in part from inhibition of insulin-like growth factor (IGF) action by excess serum IGF-binding proteins (IGFBPs). Excess IGFBPs in CRF serum include IGFBP-1, -2, and -3 and a diffuse approximately 24- to 28-kDa IGFBP band identified by [125I]IGF ligand blot. The present studies characterized this diffuse approximately 24- to 28-kDa band. Initial studies identified this band as IGFBP-6, because it was immunoprecipitated by antiserum raised against a synthetic peptide of human IGFBP-6 (hIGFBP-6). Additional [125I]IGF ligand blots found that the immunoprecipitated band was 1) recognized by [125I]IGF-II but not [125I]IGF-1, 2) more abundant in CRF than in normal serum, and 3) more abundant in serum from dialyzed than nondialyzed prepubertal CRF children. Using the hIGFBP-6 antiserum in a specific and sensitive RIA, we found that serum IGFBP-6 levels were 4.7 +/- 1.7 nmol/L in 10 normal prepubertal children, 21.4 +/- 6.1 nmol/L in 44 nondialyzed prepubertal CRF children, 73.5 +/- 14.4 nmol/L in 7 dialyzed prepubertal CRF children, and 94.6 +/- 26.2 nmol/L in 14 dialyzed pubertal CRF children. IGFBP-6 levels were also elevated in 71 nondialyzed European children with CRF. In nondialyzed CRF children, serum IGFBP-6 levels 1) correlated inversely with the glomerular filtration rate, 2) did not correlate with height SD score, and 3) were not altered by 12 months of daily recombinant hGH treatment. In summary, a specific antiserum and RIA were used to demonstrate elevated levels of intact IGF-II-binding IGFBP-6 in serum of CRF children. We postulate that the excess IGFBP-6 may modulate the action of IGF-II on target tissues.
以往研究表明,慢性肾功能衰竭(CRF)患儿生长发育迟缓部分是由于血清中过量的胰岛素样生长因子结合蛋白(IGFBP)抑制了胰岛素样生长因子(IGF)的作用。CRF血清中过量的IGFBP包括IGFBP-1、-2和-3以及通过[125I]IGF配体印迹法鉴定的一条弥散的约24至28 kDa的IGFBP条带。本研究对这条弥散的约24至28 kDa的条带进行了表征。初步研究将这条带鉴定为IGFBP-6,因为它被针对人IGFBP-6(hIGFBP-6)合成肽产生的抗血清免疫沉淀。额外的[125I]IGF配体印迹发现,免疫沉淀的条带1)可被[125I]IGF-II识别但不能被[125I]IGF-1识别,2)在CRF中比正常血清中更丰富,3)在透析的青春期前CRF患儿血清中比未透析的更丰富。使用hIGFBP-6抗血清进行特异性和灵敏的放射免疫分析(RIA),我们发现10名正常青春期前儿童血清IGFBP-6水平为4.7±1.7 nmol/L,44名未透析的青春期前CRF患儿为21.4±6.1 nmol/L,7名透析的青春期前CRF患儿为73.5±14.4 nmol/L,14名透析的青春期CRF患儿为94.6±26.2 nmol/L。71名未透析的欧洲CRF患儿的IGFBP-6水平也升高。在未透析的CRF患儿中,血清IGFBP-6水平1)与肾小球滤过率呈负相关,2)与身高标准差评分无相关性,3)每日重组人生长激素(hGH)治疗12个月后无变化。总之,使用特异性抗血清和RIA证明CRF患儿血清中完整的IGF-II结合IGFBP-6水平升高。我们推测过量的IGFBP-6可能调节IGF-II对靶组织的作用。